docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-6-7-14docru-191Research ArticleПСИХИАТРИЯPSYCHIATRYМаркеры воспаления при шизофрении для науки и практикиInflammatory Markers in Schizophrenia Patients: Scientific and Practical Significancehttps://orcid.org/0000-0001-5390-6007ЗозуляС.ZozulyaS. A.

Зозуля Светлана Александровна  — к. б. н., ведущий научный сотрудник лаборатории нейроиммунологии 

 115522, г. Москва, Каширское ш., д. 34 

34 Kashirskoye Highway, Moscow,  115522

s.ermakova@mail.ruhttps://orcid.org/0000-0002-2445-8628СармановаЗ. В.SarmanovaZ. V.

Сарманова Зоя Викторовна  — к. м. н., научный сотрудник лаборатории нейроиммунологии 

 115522, г. Москва, Каширское ш., д. 34 

34 Kashirskoye Highway, Moscow,  115522

sarmanova@list.ruhttps://orcid.org/0000-0003-3745-8413ОтманИ. Н.OtmanI. N.

Отман Ирина Николаевна — к. б. н., научный сотрудник лаборатории нейроиммунологии 

 115522, г. Москва, Каширское ш., д. 34 

34 Kashirskoye Highway, Moscow,  115522

irinaot@mail.ruhttps://orcid.org/0000-0001-5148-3864КлюшникТ. П.KlyushnikT. P.

Клюшник Татьяна Павловна — д. м. н., профессор, руководитель лаборатории нейроиммунологии, директор 

 115522, г. Москва, Каширское ш., д. 34 

34 Kashirskoye Highway, Moscow,  115522

klushnik2004@mail.ruФГБНУ «Научный центр психического здоровья»РоссияFederal State Budgetary Scientific Institution «Mental Health Research Centre»Russian Federation202318022025226НЕВРОЛОГИЯ ПСИХИАТРИЯ714Copyright © Зозуля С.A., Сарманова З.В., Отман И.Н., Клюшник Т.П., 20252025Зозуля С., Сарманова З.В., Отман И.Н., Клюшник Т.П.Zozulya S.A., Sarmanova Z.V., Otman I.N., Klyushnik T.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/191Цель обзора

Цель обзора: представить данные литературы и результаты собственных исследований относительно воспалительных биомаркеров, выявляемых с диагностической и прогностической целью у пациентов с шизофренией.

Основные положения

Основные положения. Особое внимание уделяется медицинской технологии «Нейроиммунотест», разработанной в ФГБНУ «Научный центр психического здоровья», и ее использованию для изучения патогенеза шизофрении, особенностей состояния иммунной системы при различных психопатологических расстройствах, а также для мониторинга, прогноза заболевания и оценки эффективности терапии.

Заключение

Заключение. Данные литературы, а также результаты собственных исследований свидетельствуют о ключевой роли иммунных механизмов, и в первую очередь воспаления, в формировании психопатологических расстройств у пациентов с шизофренией. Стратификация пациентов с шизофренией не только по особенностям клинической симптоматики, но и по профилю иммунных маркеров позволяет объективизировать их состояние и прогнозировать эффективность персонифицированной терапии, в связи с чем этот подход представляет интерес для практического использования в клинической психиатрии.

Objective

Objective: To present literature data and results of own studies of inflammatory biomarkers identified in schizophrenia patients for diagnostic and forecasting purposes.

Key points

Key points. Special attention is paid to the medical technique called Neuroimmunotest developed at the Scientific Centre for Mental Health and its use in the study of schizophrenia pathogenesis, immune system status in various psychopathologic disorders, as well as for disease monitoring, forecasting and therapy efficiency assessment.

Conclusion

Conclusion. The literature data and results of own studies demonstrate the key role of immune mechanisms, primarily of inflammation, in the development of psychopathologic disorders in schizophrenia patients. Classification of schizophrenia patients not only on the basis of clinical manifestations, but also using the immune marker profile makes it possible to objectify their condition and forecast the efficiency of personified therapy; therefore, this approach is of interest for practical application in clinical psychiatry. 

воспалениебиомаркерынейроиммунотестуровень активации иммунной системышизофренияinflammationbiomarkersneuroimmunotestlevel of immune system activationschizophreniaReferencesBarichello T., Simoes L.R., Quevedo J., Zhang X.Y. Microglial activation and psychotic disorders: evidence from pre-clinical and clinical studies. Curr. Top. Behav. Neurosci. 2020;44:161–205. DOI: 10.1007/7854_2018_81Barichello T., Simoes L.R., Quevedo J., Zhang X.Y. Microglial activation and psychotic disorders: evidence from pre-clinical and clinical studies. Curr. Top. Behav. Neurosci. 2020;44:161–205. DOI: 10.1007/7854_2018_81Martos D., Tuka B., Tanaka M., Vécsei L. et al. Memory enhancement with kynurenic acid and its mechanisms in neurotransmission. Biomedicines. 2022;10(4):849. DOI: 10.3390/biomedicines10040849Martos D., Tuka B., Tanaka M., Vécsei L. et al. Memory enhancement with kynurenic acid and its mechanisms in neurotransmission. Biomedicines. 2022;10(4):849. DOI: 10.3390/biomedicines10040849Najjar S., Pearlman D.M., Alper K., Najjar A. et al. Neuroinflammation and psychiatric illness. J. Neuroinflammation. 2013;10:43. DOI: 10.1186/1742-2094-10-43Najjar S., Pearlman D.M., Alper K., Najjar A. et al. Neuroinflammation and psychiatric illness. J. Neuroinflammation. 2013;10:43. DOI: 10.1186/1742-2094-10-43Ermakov E.A., Mednova I.A., Boiko A.S., Buneva V.N. et al. Chemokine dysregulation and neuroinflammation in schizophrenia: a systematic review. Int. J. Mol. Sci. 2023;24(3):2215. DOI: 10.3390/ijms24032215Ermakov E.A., Mednova I.A., Boiko A.S., Buneva V.N. et al. Chemokine dysregulation and neuroinflammation in schizophrenia: a systematic review. Int. J. Mol. Sci. 2023;24(3):2215. DOI: 10.3390/ijms24032215Jeppesen R., Orlovska-Waast S., Sørensen N.V., Christensen R.H.B. et al. Cerebrospinal fluid and blood biomarkers of neuroinflammation and blood-brain barrier in psychotic disorders and individually matched healthy controls. Schizophr. Bull. 2022;48(6):1206–16. DOI: 10.1093/schbul/sbac098Jeppesen R., Orlovska-Waast S., Sørensen N.V., Christensen R.H.B. et al. Cerebrospinal fluid and blood biomarkers of neuroinflammation and blood-brain barrier in psychotic disorders and individually matched healthy controls. Schizophr. Bull. 2022;48(6):1206–16. DOI: 10.1093/schbul/sbac098Mostafa M., Elwasify M., Fathy A.A., Abdelsalam M. Toll-Like Receptor 4 gene polymorphisms and susceptibility to schizophrenia: a case-control study. Immunol. Invest. 2022;51(7):2009–24. DOI: 10.1080/08820139.2022.2093118Mostafa M., Elwasify M., Fathy A.A., Abdelsalam M. Toll-Like Receptor 4 gene polymorphisms and susceptibility to schizophrenia: a case-control study. Immunol. Invest. 2022;51(7):2009–24. DOI: 10.1080/08820139.2022.2093118Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr. Bull. 2018;44(5):973–82. DOI: 10.1093/schbul/sby024Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr. Bull. 2018;44(5):973–82. DOI: 10.1093/schbul/sby024Малашенкова И.К., Крынский С.А., Огурцов Д.П., Мамошина М.В. и др. Роль иммунной системы в патогенезе шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(12):72– 80. DOI: 10.17116/jnevro201811812172Malashenkova I.K., Krynskiy S.A., Ogurtsov D.P., Mamoshina M.V. et al. A role of the immune system in the pathogenesis of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12):72–80. (in Russian). DOI: 10.17116/jnevro201811812172Romeo B., Brunet-Lecomte M., Martelli C., Benyamina A. Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis. Int. J. Neuropsychopharmacol. 2018;21(9):828– 36. DOI: 10.1093/ijnp/pyy062Romeo B., Brunet-Lecomte M., Martelli C., Benyamina A. Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis. Int. J. Neuropsychopharmacol. 2018;21(9):828– 36. DOI: 10.1093/ijnp/pyy062Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y. et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry. 2004;65(7):940–7. DOI: 10.4088/jcp.v65n0710Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y. et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry. 2004;65(7):940–7. DOI: 10.4088/jcp.v65n0710Dudzińska E., Szymona K., Bogucki J., Koch W. et al. Increased markers of oxidative stress and positive correlation low-grade inflammation with positive symptoms in the first episode of schizophrenia in drug-naïve patients. J. Clin. Med. 2022;11(9):2551. DOI: 10.3390/jcm11092551Dudzińska E., Szymona K., Bogucki J., Koch W. et al. Increased markers of oxidative stress and positive correlation low-grade inflammation with positive symptoms in the first episode of schizophrenia in drug-naïve patients. J. Clin. Med. 2022;11(9):2551. DOI: 10.3390/jcm11092551Goldsmith D.R., Haroon E., Miller A.H., Strauss G.P. et al. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr. Res. 2018;199:281–4. DOI: 10.1016/j.schres.2018.02.048Goldsmith D.R., Haroon E., Miller A.H., Strauss G.P. et al. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr. Res. 2018;199:281–4. DOI: 10.1016/j.schres.2018.02.048Goldsmith D.R., Haroon E., Miller A.H., Addington J. et al. Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain Behav. Immun. 2019;76:268–74. DOI: 10.1016/j.bbi.2018.11.315Goldsmith D.R., Haroon E., Miller A.H., Addington J. et al. Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain Behav. Immun. 2019;76:268–74. DOI: 10.1016/j.bbi.2018.11.315Momtazmanesh S., Zare-Shahabadi A., Rezaei N. Cytokine alterations in schizophrenia: an updated review. Front. Psychiatry. 2019;10:892. DOI: 10.3389/fpsyt.2019.00892Momtazmanesh S., Zare-Shahabadi A., Rezaei N. Cytokine alterations in schizophrenia: an updated review. Front. Psychiatry. 2019;10:892. DOI: 10.3389/fpsyt.2019.00892Patlola S.R., Donohoe G., McKernan D.P. The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: a systematic review and meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2023;121:110668. DOI: 10.1016/j.pnpbp.2022.110668Patlola S.R., Donohoe G., McKernan D.P. The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: a systematic review and meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2023;121:110668. DOI: 10.1016/j.pnpbp.2022.110668Alkan E., Davies G., Evans S.L. Cognitive impairment in schizophrenia: relationships with cortical thickness in fronto-temporal regions, and dissociability from symptom severity. NPJ Schizophr. 2021;7(1):20. DOI: 10.1038/s41537-021-00149-0Alkan E., Davies G., Evans S.L. Cognitive impairment in schizophrenia: relationships with cortical thickness in fronto-temporal regions, and dissociability from symptom severity. NPJ Schizophr. 2021;7(1):20. DOI: 10.1038/s41537-021-00149-0Ушаков В.Л., Малашенкова И.К., Костюк Г.П., Захарова Н.В. и др. Связь между воспалением, когнитивными нарушениями и данными нейровизуализации при шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(11):70–8. DOI: 10.17116/jnevro202012011170Ushakov V.L., Malashenkova I.K., Kostyuk G.P., Zakharova N.V. et al. The relationship between inflammation, cognitive disorders and neuroimaging data in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(11):70–8. (in Russian). DOI: 10.17116/jnevro202012011170Hoseth E.Z., Westlye L.T., Hope S., Dieset I. et al. Association between cytokine levels, verbal memory and hippocampus volume in psychotic disorders and healthy controls. Acta Psychiatr. Scand. 2016;133(1):53–62. DOI: 10.1111/acps.12467Hoseth E.Z., Westlye L.T., Hope S., Dieset I. et al. Association between cytokine levels, verbal memory and hippocampus volume in psychotic disorders and healthy controls. Acta Psychiatr. Scand. 2016;133(1):53–62. DOI: 10.1111/acps.12467Fu G., Zhang W., Dai J., Liu J. et al. Increased peripheral Interleukin 10 relate to white matter integrity in schizophrenia. Front. Neurosci. 2019;13:52. DOI: 10.3389/fnins.2019.00052Fu G., Zhang W., Dai J., Liu J. et al. Increased peripheral Interleukin 10 relate to white matter integrity in schizophrenia. Front. Neurosci. 2019;13:52. DOI: 10.3389/fnins.2019.00052Moreno C., Parellada M., MacDowell K.S., García-Bueno B. et al.; from the FLAMM-PEPs study, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis. Eur. Child Adolesc. Psychiatry. 2019;28(10):1395–1405. DOI: 10.1007/s00787-019-01295-8Moreno C., Parellada M., MacDowell K.S., García-Bueno B. et al.; from the FLAMM-PEPs study, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis. Eur. Child Adolesc. Psychiatry. 2019;28(10):1395–1405. DOI: 10.1007/s00787-019-01295-8Perry B.I., Zammit S., Jones P.B., Khandaker G.M. Childhood inflammatory markers and risks for psychosis and depression at age 24: examination of temporality and specificity of association in a population-based prospective birth cohort. Schizophr. Res. 2021;230:69–76. DOI: 10.1016/j.schres.2021.02.008Perry B.I., Zammit S., Jones P.B., Khandaker G.M. Childhood inflammatory markers and risks for psychosis and depression at age 24: examination of temporality and specificity of association in a population-based prospective birth cohort. Schizophr. Res. 2021;230:69–76. DOI: 10.1016/j.schres.2021.02.008Mondelli V., Blackman G., Kempton M.J., Pollak T.A. et al.; EU GEI High Risk Study; McGuire P. Serum immune markers and transition to psychosis in individuals at clinical high risk. Brain Behav. Immun. 2023;110:290–6. DOI: 10.1016/j.bbi.2023.03.014Mondelli V., Blackman G., Kempton M.J., Pollak T.A. et al.; EU GEI High Risk Study; McGuire P. Serum immune markers and transition to psychosis in individuals at clinical high risk. Brain Behav. Immun. 2023;110:290–6. DOI: 10.1016/j.bbi.2023.03.014Dawidowski B., Górniak A., Podwalski P., Lebiecka Z. et al. The role of cytokines in the pathogenesis of schizophrenia. J. Clin. Med. 2021;10(17):3849. DOI: 10.3390/jcm10173849Dawidowski B., Górniak A., Podwalski P., Lebiecka Z. et al. The role of cytokines in the pathogenesis of schizophrenia. J. Clin. Med. 2021;10(17):3849. DOI: 10.3390/jcm10173849Lestra V., Romeo B., Martelli C., Benyamina A. et al. Could CRP be a differential biomarker of illness stages in schizophrenia? A systematic review and meta-analysis. Schizophr. Res. 2022;246:175–86. DOI: 10.1016/j.schres.2022.06.026Lestra V., Romeo B., Martelli C., Benyamina A. et al. Could CRP be a differential biomarker of illness stages in schizophrenia? A systematic review and meta-analysis. Schizophr. Res. 2022;246:175–86. DOI: 10.1016/j.schres.2022.06.026Минаев С.В., Исаева А.В., Обедин А.Н., Болотов Ю.Н. и др. С-реактивный белок — главный маркер динамики течения острых воспалительных процессов в клинических условиях. Медицинский вестник Северного Кавказа. 2011;2:95–9. URL: https://cyberleninka.ru/article/n/s-reaktivnyy-belok-glavnyy-marker-dinamiki-techeniyaostryh-vospalitelnyh-protsessov-v-klinicheskih-usloviyah/viewer (дата обращения — 03.06.2023).Minaev S.V., Isaeva A.V., Obedin A.N., Bolotov Y.N. et al. C-reactive protein as a key marker of the course of acute inflammatory processes in clinical settings. Medicinskij vestnik Severnogo Kavkaza. 2011;2:95–9. (in Russian). URL: https://cyberleninka.ru/article/n/s-reaktivnyy-belok-glavnyy-marker-dinamiki-techeniyaostryh-vospalitelnyh-protsessov-v-klinicheskih-usloviyah/viewer (дата обращения — 03.06.2023).Sahpolat M., Ayar D., Ari M., Karaman M.A. Elevated monocyte to high-density lipoprotein ratios as an inflammation markers for schizophrenia patients. Clin. Psychopharmacol. Neurosci. 2021;19(1):112–6. DOI: 10.9758/cpn.2021.19.1.112Sahpolat M., Ayar D., Ari M., Karaman M.A. Elevated monocyte to high-density lipoprotein ratios as an inflammation markers for schizophrenia patients. Clin. Psychopharmacol. Neurosci. 2021;19(1):112–6. DOI: 10.9758/cpn.2021.19.1.112Mednova I.A., Boiko A.S., Kornetova E.G., Semke A.V. et al. Cytokines as potential biomarkers of clinical characteristics of schizophrenia. Life. 2022;12(12):1972. DOI: 10.3390/life12121972Mednova I.A., Boiko A.S., Kornetova E.G., Semke A.V. et al. Cytokines as potential biomarkers of clinical characteristics of schizophrenia. Life. 2022;12(12):1972. DOI: 10.3390/life12121972Mondelli V., Ciufolini S., Murri M.B., Bonaccorso S. et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 2015;41(5):1162–70. DOI: 10.1093/schbul/sbv028Mondelli V., Ciufolini S., Murri M.B., Bonaccorso S. et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 2015;41(5):1162–70. DOI: 10.1093/schbul/sbv028Feng Z., Zhang Y., You X., Zhang W. et al. Effects of risperidone on blood levels of Interleukin-6 in schizophrenia: a meta-analysis. Medicine (Baltimore). 2020;99(15):e19694. DOI: 10.1097/MD.0000000000019694Feng Z., Zhang Y., You X., Zhang W. et al. Effects of risperidone on blood levels of Interleukin-6 in schizophrenia: a meta-analysis. Medicine (Baltimore). 2020;99(15):e19694. DOI: 10.1097/MD.0000000000019694Lee E.E., Ancoli-Israel S., Eyler L.T., Tu X.M. et al. Sleep disturbances and inflammatory biomarkers in schizophrenia: focus on sex differences. Am. J. Geriatr. Psychiatry. 2019;27(1):21–31. DOI: 10.1016/j.jagp.2018.09.017Lee E.E., Ancoli-Israel S., Eyler L.T., Tu X.M. et al. Sleep disturbances and inflammatory biomarkers in schizophrenia: focus on sex differences. Am. J. Geriatr. Psychiatry. 2019;27(1):21–31. DOI: 10.1016/j.jagp.2018.09.017Adamowicz D.H.., Shilling P.D., Palmer B.W., Nguyen T.T. et al. Associations between inflammatory marker profiles and neurocognitive functioning in people with schizophrenia and nonpsychiatric comparison subjects. J. Psychiatr. Res. 2022;149:106– 13. DOI: 10.1016/j.jpsychires.2022.02.029Adamowicz D.H.., Shilling P.D., Palmer B.W., Nguyen T.T. et al. Associations between inflammatory marker profiles and neurocognitive functioning in people with schizophrenia and nonpsychiatric comparison subjects. J. Psychiatr. Res. 2022;149:106– 13. DOI: 10.1016/j.jpsychires.2022.02.029Zhu X., Zhou J., Zhu Y., Yan F. et al. Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in schizophrenia. Australas. Psychiatry. 2022;30(1):95–9. DOI: 10.1177/10398562211022753Zhu X., Zhou J., Zhu Y., Yan F. et al. Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in schizophrenia. Australas. Psychiatry. 2022;30(1):95–9. DOI: 10.1177/10398562211022753Räuber S., Heming M., Repple J., Ruland T. et al. Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. Mol. Psychiatry. 2021;26(12):7661–70. DOI: 10.1038/s41380-021-01244-5Räuber S., Heming M., Repple J., Ruland T. et al. Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. Mol. Psychiatry. 2021;26(12):7661–70. DOI: 10.1038/s41380-021-01244-5Balcioglu Y.H., Kirlioglu S.S. C-reactive protein/albumin and neutrophil/albumin ratios as novel inflammatory markers in patients with schizophrenia. Psychiatry Investig. 2020;17(9):902–10. DOI: 10.30773/pi.2020.0185Balcioglu Y.H., Kirlioglu S.S. C-reactive protein/albumin and neutrophil/albumin ratios as novel inflammatory markers in patients with schizophrenia. Psychiatry Investig. 2020;17(9):902–10. DOI: 10.30773/pi.2020.0185Kılıç N., Tasci G., Yılmaz S., Öner P. et al. Monocyte/HDL cholesterol ratios as a new inflammatory marker in patients with schizophrenia. J. Pers. Med. 2023;13(2):276. DOI: 10.3390/jpm13020276Kılıç N., Tasci G., Yılmaz S., Öner P. et al. Monocyte/HDL cholesterol ratios as a new inflammatory marker in patients with schizophrenia. J. Pers. Med. 2023;13(2):276. DOI: 10.3390/jpm13020276Брусов О.С., Матвеев И.А., Кириллов П.С., Фактор М.И. и др. Оценка риска тромботических нарушений у больных шизофренией и шизоаффективными расстройствами в остром периоде болезни с использованием технологии «фибринодинамика». Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(11):91–100. DOI: 10.17116/jnevro201711711191-100Brusov O.S., Matveev И.A., Kirillov P.S., Factor M.I. et al. Risk assessment of thrombotic events in patients with schizophrenia and schizoaffective disorder in the acute state: the "fibrinodynamics" technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11):91–100. (in Russian). DOI: 10.17116/jnevro201711711191-100Endres D., von Zedtwitz K., Matteit I., Bünger I. et al. Spectrum of novel anti-central nervous system autoantibodies in the cerebrospinal fluid of 119 patients with schizophreniform and affective disorders. Biol. Psychiatry. 2022;92(4):261–74. DOI: 10.1016/j.biopsych.2022.02.010Endres D., von Zedtwitz K., Matteit I., Bünger I. et al. Spectrum of novel anti-central nervous system autoantibodies in the cerebrospinal fluid of 119 patients with schizophreniform and affective disorders. Biol. Psychiatry. 2022;92(4):261–74. DOI: 10.1016/j.biopsych.2022.02.010Bishop J.R., Zhang L., Lizano P. Inflammation subtypes and translating inflammation-related genetic findings in schizophrenia and related psychoses: a perspective on pathways for treatment stratification and novel therapies. Harv. Rev. Psychiatry. 2022;30(1):59–70. DOI: 10.1097/HRP.0000000000000321Bishop J.R., Zhang L., Lizano P. Inflammation subtypes and translating inflammation-related genetic findings in schizophrenia and related psychoses: a perspective on pathways for treatment stratification and novel therapies. Harv. Rev. Psychiatry. 2022;30(1):59–70. DOI: 10.1097/HRP.0000000000000321Sæther L.S., Ueland T., Haatveit B., Maglanoc L.A. et al. Inflammation and cognition in severe mental illness: patterns of covariation and subgroups. Mol. Psychiatry. 2023;28(3):1284–92. DOI: 10.1038/s41380-022-01924-wSæther L.S., Ueland T., Haatveit B., Maglanoc L.A. et al. Inflammation and cognition in severe mental illness: patterns of covariation and subgroups. Mol. Psychiatry. 2023;28(3):1284–92. DOI: 10.1038/s41380-022-01924-wMiller B.J., Goldsmith D.R. Evaluating the hypothesis that schizophrenia is an inflammatory disorder. Focus (Am. Psychiatr. Publ.). 2020;18(4):391–401. DOI: 10.1176/appi.focus.20200015Miller B.J., Goldsmith D.R. Evaluating the hypothesis that schizophrenia is an inflammatory disorder. Focus (Am. Psychiatr. Publ.). 2020;18(4):391–401. DOI: 10.1176/appi.focus.20200015Shivakumar V., Debnath M., Venugopal D., Rajasekaran A. et al. Influence of correlation between HLA-G polymorphism and Interleukin-6 (IL6) gene expression on the risk of schizophrenia. Cytokine. 2018;107:59–64. DOI: 10.1016/j.cyto.2017.11.016Shivakumar V., Debnath M., Venugopal D., Rajasekaran A. et al. Influence of correlation between HLA-G polymorphism and Interleukin-6 (IL6) gene expression on the risk of schizophrenia. Cytokine. 2018;107:59–64. DOI: 10.1016/j.cyto.2017.11.016Голимбет В.Е., Клюшник Т.П. Молекулярно-генетический и иммунологический аспекты формирования психопатологических симптомов при шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(10):66–71. Golimbet V.E., Klyushnik T.P. Molecular-genetic and immunological aspects of the formation of psychopathological symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(10):66– 71. (in Russian). DOI: 10.17116/jnevro202212210166Golimbet V.E., Klyushnik T.P. Molecular-genetic and immunological aspects of the formation of psychopathological symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(10):66– 71. (in Russian). DOI: 10.17116/jnevro202212210166Клюшник Т.П., Зозуля С.А., Андросова Л.В., Сарманова З.В. и др. Иммунологический мониторинг эндогенных приступообразных психозов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;114(2):37–41. URL: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova/2014/2/downloads/ru/031997-7298201427 (дата обращения — 04.06.2023).Klyushnik T.P., Zozulya S.A., Androsova L.V., Sarmanova Z.V. et al. Immunological monitoring of endogenous attack-like psychoses. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(2):37–41. (in Russian). URL: https://www. mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova/2014/2/downloads/ru/031997-7298201427 (дата обращения — 04.06.2023).Клюшник Т.П., Зозуля С.А., Олейчик И.В. Маркеры активации иммунной системы в мониторинге течения эндогенных психических заболеваний. В кн.: Бохан Н.А., Иванова С.А., ред. Биологические маркеры шизофрении: поиск и клиническое применение. Новосибирск: изд-во СО РАН; 2017: 34–46.Klyushnik T.P., Zozulya S.A., Oleichik I.V. Novosibirsk. Markers of immune system activation in monitoring of the course of endogenous mental disorders. In: Bokhan N.A., Ivanova S.A. (ed.). Biological markers of schizophrenia: search and clinical application. Novosibirsk: Publishing House of the Siberian branch of the Russian Academy of Sciences. Izd-vo SO RAN; 2017: 34–46. (in Russian).Парамонова Н.С., Карчевский А.А., Шулика В.Р. Диагностика и прогнозирование течения деструктивно-язвенных поражений слизистой оболочки желудка и двенадцатиперстной кишки на основе определения протеолитически-антипротеолитической системы сыворотки крови у детей с дисплазией соединительной ткани. Журнал Гродненского государст венного медицинского университета. 2017;2:210–5. URL: https://cyberleninka.ru/article/n/diagnostikai-prognozirovanie-techeniya-destruktivno-yazvennyh-porazheniyslizistoy-obolochki-zheludka-i-dvenadtsatiperstnoy-kishki/viewer (дата обращения — 04.06.2023).Paramonova N.S., Karchevskij A.A., SHulika V.R. Diagnosis and forecasting of the course of destructive ulcerative lesions on the gastric and duodenal mucosa on the basis of the proteolytically antiproteolytic serum system in children with connective tissue dysplasia. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta. 2017;2:210–5. (in Russian). URL: https://cyberleninka.ru/article/n/diagnostikai-prognozirovanie-techeniya-destruktivno-yazvennyh-porazheniyslizistoy-obolochki-zheludka-i-dvenadtsatiperstnoy-kishki/viewer (дата обращения — 04.06.2023).Santos-Lima B., Pietronigro E.C., Terrabuio E., Zenaro E. et al. The role of neutrophils in the dysfunction of central nervous system barriers. Front. Aging Neurosci. 2022;14:965169. DOI: 10.3389/fnagi.2022.965169Santos-Lima B., Pietronigro E.C., Terrabuio E., Zenaro E. et al. The role of neutrophils in the dysfunction of central nervous system barriers. Front. Aging Neurosci. 2022;14:965169. DOI: 10.3389/fnagi.2022.965169Сарманова З.В., Зозуля С.А., Отман И.Н., Прохорова Т.А. и др. Связь биомаркеров воспаления, субпопуляционного состава моноцитов и активности тромбоцитарных ферментов у больных шизофренией. Патогенез. 2022;20(3):121–2. DOI: 10.25557/2310-0435.2022.03.121-122Sarmanova Z.V., Zozulya S.A., Otman I.N., Prokhorova T.A. et al. Relationship between biomarkers of inflammation, subpopulation composition of monocytes and activity of platelet enzymes in patients with schizophrenia. Pathogenesis. 2022;20(3):121–2. (in Russian). DOI: 10.25557/2310-0435.2022.03.121-122Клюшник Т.П., Смулевич А.Б., Зозуля С.А., Борисова П.О. и др. Кататония: иммунологический аспект (на модели двигательных симптомокомплексов в клинике шизофрении и расстройств шизофренического спектра). Психиатрия. 2022;20(1):17–25. DOI: 10.30629/2618-6667-2022-20-1-17-25Klyushnik T.P., Smulevich A.B., Zozulya S.A., Borisova P.O. et al. Catatonia: immunological aspect (on the model of motor symptom complexes in the clinic of schizophrenia and schizophrenic spectrum disorders). Psychiatry. 2022;20(1):17–25. (in Russian). DOI: 10.30629/2618-6667-2022-20-1-17-25Клюшник Т.П., Смулевич А.Б., Зозуля С.А., Романов Д.В. и др. Клинико-иммунологические аспекты бредовых расстройств при параноидной шизофрении. Психиатрия. 2023;21(2):6– 16. DOI: 10.30629/2618-6667-2023-21-2-6-16Klyushnik T.P., Smulevich A.B., Zozulya S.A., Romanov D.V. et al. Clinical and immunological aspects of delusional disorders in paranoid schizophrenia. Delusional disorders in paranoid schizophrenia (immunological aspects). Psychiatry. 2023;21(2):6– 16. (in Russian). DOI: 10.30629/2618-6667-2023-21-2-6-16Якимец А.В., Зозуля С.А., Олейчик И.В., Клюшник Т.П. Особенности динамики клинико-биологических показателей астенического симптомокомплекса у больных шизофренией в процессе иммунотропной терапии. Журнал неврологии и психиатрии им. C.C. Корсакова. 2018;118(3):70–6. DOI: 10.17116/jnevro20181183170-76Yakimets A.V., Zozulya S.A., Oleĭchik I.V., Klyushnik T.P. Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3):70–6. (in Russian). DOI: 10.17116/jnevro20181183170-76Клюшник Т.П., Андросова Л.В., Симашкова Н.В., Зозуля С.А. и др. Состояние врожденного и приобретенного иммунитета у детей с психотическими формами расстройств аутистичес кого спектра. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(8):41–5. URL: https://www.mediasphera.ru/issues/zhurnal-nevrologiii-psikhiatrii-im-s-s-korsakova/2011/8/downloads/ru/031997-7298201189 (дата обращения — 12.07.2023).Klyushnik T.P., Androsova L.V., Simashkova N.V., Zozulya S.A. et al. Innate and adaptive immunity in children with psychotic forms of autism-spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(8):41–5. (in Russian). URL: https://www.mediasphera.ru/issues/zhurnal-nevrologiii-psikhiatrii-im-s-s-korsakova/2011/8/downloads/ru/031997-7298201189 (дата обращения — 12.07.2023).Yao H.W., Kuan C.Y. Early neutrophil infiltration is critical for inflammation-sensitized hypoxic-ischemic brain injury in newborns. J. Cereb. Blood Flow Metab. 2020;40(11):2188–200. DOI: 10.1177/0271678X19891839Yao H.W., Kuan C.Y. Early neutrophil infiltration is critical for inflammation-sensitized hypoxic-ischemic brain injury in newborns. J. Cereb. Blood Flow Metab. 2020;40(11):2188–200. DOI: 10.1177/0271678X19891839Prinz M., Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat. Neurosci. 2017;20(2):136–44. DOI: 10.1038/nn.4475Prinz M., Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat. Neurosci. 2017;20(2):136–44. DOI: 10.1038/nn.4475

The authors declare that there are no conflicts of interest present.